MGC Pharmaceuticals - Director/PDMR Shareholding

RNS Number : 3970Z

MGC Pharmaceuticals Limited

11 January 2024

MGC Pharmaceuticals Ltd.

PDMR Notification

11 January 2024

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.

The shares subject of this notice were issued to the PDMR's as part of their working contracts and as consideration for services rendered in lieu of cash payments

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Amir Polak
2	Reason for the notification
(a)	Position		Chief Pharmaceutical Development Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments
(d)	Currency	Price		Volume	Total
	AUD	A$0.55		600,000	A$330,000
	Aggregated information
	AUD	A$0.55		600,000	A$330,000
(e)	Date of transaction		10 January 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Sabina Suljakovic
2	Reason for the notification
(a)	Position		Vice President of Global Quality
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments
(d)	Currency	Price		Volume	Total
	AUD	A$0.55		17,000	A$9,350
	Aggregated information
	AUD	A$0.55		17,000	A$9,350
(e)	Date of transaction		10 January 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Yair Tal
2	Reason for the notification
(a)	Position		Chief Information Security Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments
(d)	Currency	Price		Volume	Total
	AUD	A$0.55		300,000	A$165,000
	Aggregated information
	AUD	A$0.55		300,000	A$165,000
(e)	Date of transaction		10 January 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Yifat Steuer
2	Reason for the notification
(a)	Position		Chief Operating Officer and Deputy CEO
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments
(d)	Currency	Price		Volume	Total
	AUD	A$0.55		1,100,000	A$605,000
	Aggregated information
	AUD	A$0.55		1,100,000	A$605,000
(e)	Date of transaction		10 January 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Rowan Harland
2	Reason for the notification
(a)	Position		Company Secretary
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments
(d)	Currency	Price		Volume	Total
	AUD	A$0.55		7,000	A$3,850
	Aggregated information
	AUD	A$0.55		7,000	A$3,850
(e)	Date of transaction		10 January 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Ana Arhar Oblak
2	Reason for the notification
(a)	Position		Group Financial Controller
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments
(d)	Currency	Price		Volume	Total
	AUD	A$0.55		10,000	A$5,500
	Aggregated information
	AUD	A$0.55		10,000	A$5,500
(e)	Date of transaction		10 January 2024
(f)	Place of transaction		Outside a trading venue

-Ends-

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@mgcpharma.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland

Company Secretary

+61 8 6555 2950

info@mgcpharma.co.uk

UK IR/PR Advisers

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen

+44 203 934 6630

mgcpharma@investor-focus.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock

+44 203 179 5300

aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKFLBFZFLEBBL]]>